Interstitial pneumonia signals of apalutamide, darolutamide, and enzalutamide in FAERS and JADER. [PDF]
Zheng Z, Zhao Z, Jin P.
europepmc +1 more source
Advancements and future directions in transformative therapies of prostate cancer. [PDF]
Zhao J, Tang B, Zeng H, Wei Q.
europepmc +1 more source
TMEM59L promotes neuroendocrine differentiation and enzalutamide resistance in prostate cancer by regulating MUC1/β-catenin/MYC axis. [PDF]
Guo X +7 more
europepmc +1 more source
Redefining the standard of care for high-risk biochemical recurrence of prostate cancer after definitive therapy: insights from the EMBARK final analysis. [PDF]
Sawazaki H.
europepmc +1 more source
Pharmacovigilance of Androgen Receptor Pathway Inhibitors in Prostate Cancer: The Impact of Docetaxel Co-Reporting. [PDF]
Alkan O +3 more
europepmc +1 more source
EPS8 Differentially Regulates Antioxidant Defense and Mitochondrial Homeostatic Signaling in LNCaP and Enzalutamide-resistant LNCaP Cells. [PDF]
Chen SH +6 more
europepmc +1 more source
Apalutamide-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome in a Patient With Metastatic Prostate Cancer: A Case Report. [PDF]
Kabir S, Cormode L.
europepmc +1 more source

